Merck (MRK), Samsung Bioepis Announce SB4, SB2 Met Primary Phase 3 Endpoints
Tweet Send to a Friend
Merck (NYSE: MRK) and Samsung Bioepis Co., Ltd., announced that pivotal Phase 3 clinical studies of SB4, an investigational biosimilar ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
